

South Carolina Board of Pharmacy Board Meeting Minutes/Motions

9:00 a.m. November 19-20, 2025

Synergy Business Park

110 Centerview Drive, Columbia, South Carolina
Kingstree Building, Lowcountry Conference Room

Dr. Smith called the meeting to order and announced the meeting is being held in accordance with the Section 30-4-8 of the South Carolina Freedom of Information Act by notice sent to The State Newspaper, Associated Press, WIS TV and all other Requesting persons, organizations or news media. In addition, notice was posted on the bulletin Board at the main entrance of the Kingstree Building.

BOARD MEMBER PRESENT:

Mary Douglass Smith, PharmD, Chair

Laney S. Spigener, III, PharmD, Vice Chair

Larry Meek, R.Ph.

Jarrod Tippins, PharmD

Josias A. Garcia, CPT

Cassey Eunice, PharmD

Dottie Farfone, R.Ph.

Rebecca Gillespie, PharmD

Beverly Black, Public Member

SCLLR STAFF PRESENT:

Kayce Shealy, PharmD, Board Administrator

Carolyn Sutherland, Esq, Advice Counsel

Stephanie Calhoun, Program Coordinator

Sheila Young, R.Ph., Staff

Julia Bales, PharmD, Staff

Ray Trotter, R.Ph., Investigator

Jennifer Harris, PharmD, Investigator

Ivy Coleman, PharmD, Inspector

Alison Gratton, PharmD, Inspector

Douglas Murray, PharmD, Inspector

Casey Smith, Esq., Office of Disciplinary Counsel (ODC)

REPORTED BY:

Andy Taylor, Court Reporter

Cassandra Vance, Court Reporter

APPROVAL OF AGENDA

Dr. Spigener moved to approve the agenda. Ms. Farfone seconded the motion, which carried unanimously.

CONSIDERATION FOR EXCUSES FOR ABSENCES OF BOARD MEMBERS

There were no Board members absent.

APPROVAL OF OCTOBER 1-2, 2025 BOARD MEETING MINUTES AND OCTOBER 15, 2025 CALLED MEETING MINUTES

Dr. Eunice requested the minutes relating to the proposed outsourcing facility regulations to further evaluate the impact of incorporating those requirements into the regulations.

Dr. Spigener moved to approved the Call Meeting Minutes, as amended. Ms. Black seconded the motion, which carried unanimously.

CHAIRMAN'S REMARKS-Mary Douglass Smith, PharmD

Dr. Smith shared insights from the recent NABP forum, emphasizing the importance of balancing public protection, professional judgment, and the evolving healthcare landscape. She highlighted a presentation on conflicts of interest, stressing that board members must proactively identify and manage potential conflicts, with recusal being a crucial step when impartiality cannot be preserved. Dr. Smith underscored the significance of proper documentation and disclosure, noting that failure to do so can lead to severe consequences, including loss of credibility and public trust.

Dr. Smith discussed the importance of proper oversight and conflict identification in board operations, emphasizing the role of safeguarding decision integrity in public health. She highlighted the critical need for attention to compounding practices.

Dr. Smith stressed the importance of ensuring compounding preparations are safe, high quality, and lawful, emphasizing the U.S. Food and Drug Administration requirements under 503A or 503B. She highlighted real-world examples of poor compounding practices, including issues with sanitation and a case of a contaminated testosterone cream, stressing the need for rigorous oversight and documentation. Dr. Smith also touched on compliance trends, the importance of comprehensive training for compounders and inspectors, and the role of regulators in navigating complex issues for public safety.

ADMINISTRATOR'S REPORT-Kayce Shealy, PharmD

Dr. Shealy reported that license permits remain stable as of November 2025 and staff expansion is planned with a new inspector joining in January and an administrative assistant in December or January. She shared details about the fourth district election where Kevin Cogsdale, Raymond Westrick, and Tim Gentlecore are on the ballot, with ballots due by December 4th. Dr. Shealy also thanked the Board for supporting staff during Pharmacy Week and mentioned receiving communication from the Alliance for Pharmacy Compounding regarding compounding practices.

Dr. Shealy announced that pharmacist application renewals will open online on February 1st, with a new ordering of questions. She reminded pharmacists not to renew their licenses until they have met the required continuing education (CE) hours, which include 15 hours per year, at least 7.5 hours in drug therapy/patient management, as well as specific requirements for pharmacists engaged in controlled substances, immunization, and hormonal contraceptives. Dr. Shealy also noted that the exemption period for large dispensers under Drug Supply Chain Security Act (DSCSA) ends on November 27th, while small dispensers have until 2026.

Dr. Shealy introduced a new pharmacy board member manual that had been updated with current information. She invited questions about the manual and clarified that any edits should be submitted to her.

INVESTIGATIONS AND ENFORCEMENT-JENNIFER HARRIS, INVESTIGATOR, AND RAY TROTTER, INVESTIGATOR

Dr. Harris presented the following report for information purposes only: Between January 1, 2025 – November 4, 2025 there were ninety-nine (99) active investigations, two hundred eleven (211) closed cases and total complaints received are two hundred and fifty-six (256).

Investigative Review Conference (IRC) Statistical Report and Recommendations

Dr. Harris and Attorney Smith answered questions relating to the IRC recommendations.

Dr. Gillespie moved to accept the IRC recommendations. Dr. Spigener seconded the motion, which carried unanimously.

OFFICE OF DISCIPLINARY COUNSEL-CASEY SMITH, ESQ

ODC Statistical Report

Attorney Smith presented the ODC statistical report regarding disciplinary matters as of November 5, 2025. The report indicated the following: there are currently thirty-nine (39) open cases, nine (9) pending hearings and/or agreements, no cases pending closure, eight (8) cases closed since September 17, 2025, and a total of thirty (30) cases closed since January 1, 2025. Additionally, there are no pending appeals.

Three consent agreements were presented for approval.

Case# 2023-71

Dr. Gillespie moved to approve the consent agreement. Dr. Spigener seconded the motion, which carried unanimously.

Case# 2023-136

Dr. Spigener moved to approve the consent agreement. Dr. Tippins seconded the motion, which carried unanimously.

Case# 2025-2

Dr. Spigener moved to approve the consent agreement. Dr. Gillespie seconded the motion, which carried unanimously.

There were three (3) voluntary surrenders and three (3) relinquishments presented to the Board and accepted as information.

OTHER REPORTS

Board Member Travel-Mary Douglass Smith, PharmD

The Board chair noted the travel policy is included in the board manual, emphasizing that Board members attending conferences on behalf of the Board are expected to fully attend and actively participate in meetings supported by Board funds. Dr. Smith stressed the importance of wise stewardship of taxpayer funds and outlined expectations for attending meetings, including providing recaps and reports upon return. She encouraged any edits or additions to be submitted to Dr. Shealy for inclusion in the manual.

National Association of Boards of Pharmacy Committee/Task Force-Beverly Black; Dottie Farfone, RPh.; Shuler Spigener, PharmD

Ms. Black provided a recap of her participation in a task force meeting held September 15-16 in Mount Prospect, Illinois, which reviewed increasing access to medication for opioid use disorder. The task force, formed in response to a House of Delegates recommendation, focused on addressing access issues caused by legal settlements and the difficulties poor individuals face in obtaining approvals. Ms. Black explained that a new policy was developed to increase access and that a larger group, including major pharmacy associations, would be involved in future discussions.

Ms. Farfone provided her summary at a previous meeting.

Dr. Spigener stated the committee was tasked with evaluating current requirements for the Foreign Pharmacy Graduate Examination Committee (FPGEC) certification and reviewing the use of the Test of English as a Foreign Language Internet-Based Test (TOEFL IBT) exam as a requirement. He mentioned that the discussion was lively and included perspectives he had not considered before. The task force is expected to publish their recommendations, which are currently under a confidentiality agreement.

South Carolina Department of Public Health-Bureau of Drug Control Drug Enforcement Agency

Dr. Shealy reported that the South Carolina Department of Public Health Bureau of Drug Control was not present at the meeting and nothing to report.

Drug Enforcement Agency

James Osborne, with the Federal Drug Enforcement Agency in Columbia, SC introduced himself and noted they did not have an update to report at this time.

Associations

South Carolina Hospital Association (SCHA)

The report from the association was made available in the Board materials. Lara Hewitt and Jennifer Bair represented the South Carolina Hospital Association. They provided context on the association's report and concerns, particularly regarding 340B program impacts on hospital operations and pharmacy services.

Ms. Bair discussed ongoing efforts to address healthcare workforce challenges and improve access to patient care through legislative changes and partnerships with various healthcare organizations. She highlighted the importance of educating stakeholders about the 340B program, which allows hospitals to extend prescription drug access to underserved areas. She also mentioned that approximately 50-60% of South Carolina hospitals currently participate in the 340B program.

South Carolina Pharmacy Association (SCPA)

The report from the association was made available in the Board materials. A representative from the association, Brian Clark, CEO, was present to answer questions from the Board.

Mr. Clark discussed the importance of collaboration between associations and emphasized that their advocacy efforts should not undermine one another's work. It was highlighted that there is a need for a unified approach when advocating for legislation, particularly focusing on pharmacy benefit manager (PBM) reform and 340B issues. It was mentioned that they are working on creating one-pagers for both topics to ensure consistency in messaging when speaking with legislators.

South Carolina Society of Health System Pharmacists- (SCSHP)

The report from the association was made available in the Board materials. Jennifer Bair was present to speak on behalf of the association.

Dr. Bair discussed the South Carolina Society of Health Systems Pharmacists' report and their attendance at a 340B collaboration meeting. She discussed aligning initiatives with the Hospital Association and SCSHP on hospital representation on boards and on addressing safe compounding and patient access in the state. It was clarified that the distinction between SCHA and SCSHP is that SCHA focuses on all hospital operations, including pharmacy, while SCSHP is pharmacy-specific.

OLD BUSINESS

Compounding Advisory Panel

Dr. Shealy provided an update on the selection process for the compounding advisory panel. The board had called for 9 members, including 8 pharmacists and 1 technician, to serve a one-year term. As of November 14, 2025, 33 pharmacists and 8 pharmacy technicians had applied. Dr. Shealy and staff had selected 9 individuals but had not yet notified them.

Dr. Shealy proposed that one-year terms should start on January 1, 2026 and end on December 31, 2026 with individuals being asked to attend the January meeting. Dr. Smith expressed appreciation for the team's quick work in preparing for the board meeting since November 3rd. The group agreed with Dr. Shealy's proposal for the term dates.

NEW BUSINESS

Regulatory Landscape Overview-Holly Beeson, Esq, Communications and Governmental Affairs

Holly Beeson, Esq. from LLR's Office of Communications and Governmental Affairs, explained the regulatory process, starting with board votes on regulations, which are then published in the State Register. She outlined the comment period, potential Administrative Law Court hearing, and the process of taking regulations to the General Assembly. Holly detailed the steps involved in legislative review, including subcommittee and full committee hearings in both the Senate and House, and explained that if no changes are made, the regulation will go into effect after the 110-day approval period.

Ms. Beeson provided an overview of the regulatory landscape in 2025-2026, highlighting two main bills: House Bill 3021 (Regulatory Freedom Act) and a government efficiency bill in the Senate. She explained that both bills aim to reduce regulation, with the House bill focusing on sunsetting existing regulations and requiring agencies to re-promulgate them with data-driven decisions, while the Senate bill proposes creating a committee to review regulations from both individual and business perspectives. Ms. Beeson advised the board to consider the audience for future regulations, suggesting that new legislative members who may not be familiar with regulations should be kept in mind when drafting proposals.

Recovering Professionals Program (RPP) Overview-Tia Cooper, LAC, AADC, NCACI

Tia Cooper, introduced RPP to the board as a 25-year-old organization contracted to monitor and support healthcare professionals, particularly focusing on substance use disorders and other health-related issues. Ms. Cooper presented an overview of their staff structure, current program participants, and recent intakes, while explaining their reporting processes for both board-referred and voluntary cases. The conversation ended with a discussion of monitoring program evaluations by Dr. Rebecca Payne. Dr. Spigener moved to enter into closed session to discuss specific case information, which was seconded by Mr. Garcia; the motion carried unanimously.

Dr. Spigener moved to exit closed session, which was seconded by Mr. Garcia; the motion carried unanimously.

Approve CE Audit Failure Administrative Suspension and/or Consent Agreement Parameters-Kayce Shealy, PharmD

The board discussed the continuing education (CE) audit process and administrative suspension policies for pharmacists. Dr. Shealy provided that there were approximately fifty (50) failures out of 879 audited pharmacists, with a majority due to lacking specific CE requirements for controlled substance monitoring and immunization. The board reviewed the current consent agreement process, which includes providing 15 hours of CE to cover the previous period and completing the board's reciprocity course, along with a \$250 fine and public reprimand. A motion was made by Dr. Gillespie to take this matter up in executive session for legal advice, with Dr. Shealy invited to join the discussion. Dr. Spigener seconded the motion, which carried unanimously.

Dr. Gillespie moved to allow staff to issue letters to all licensees who have failed the current CE audit, giving them 10 days to come into compliance or else their license will be administratively suspended. Dr. Eunice seconded the motion, which carried unanimously.

Dr. Gillespie moved that all licensees who failed the CE audit this year have a complaint filed against their license. Dr. Spigener seconded the motion, which carried unanimously.

Review and Update Resolution Guidelines-Kayce Shealy, PharmD

The Board discussed the urgency of resolution guidelines for CE audits. Dr. Gillespie moved that this discussion be taken up in executive session with Dr. Shealy included; the motion was seconded by Mr. Garcia and carried unanimously.

Dr. Gillespie made a motion to create a task force of three members of the Board of Pharmacy, advice counsel, the administrator, pharmacy investigator and the attorney from ODC to review and update the resolution guidelines, including to add failure of the CE audit for both pharmacists and technicians. Dr. Farfone seconded the motion, which carried unanimously.

Clarification regarding additional attempts for licensing exams (MPJE, NAPLEX)-Kayce Shealy, PharmD

The board discussed policies regarding additional attempts for licensing exams, specifically the MPJE and NAPLEX, with a focus on whether to maintain the current limit of five attempts or modify it. The board reviewed previous decisions and considered allowing candidates to petition for additional attempts after their third failure, potentially requiring a study plan and board appearance. They also discussed the implications of allowing early MPJE administration and the need for data on current exam attempts. The board agreed to table the discussion on early administration of the MPJE until the following day to allow time for further consideration.

Dr. Tippins moved that a candidate be allowed to take the exam three times, and subsequent requests to retake the exam will require candidates to appear before the Board. The motion was rescinded.

Dr. Gillespie moved that a candidate seeking additional attempts at an exam, whether it be the NAPLEX or the MPJE, after three failed attempts must appear before the Board of Pharmacy and present a study plan effective June 1, 2026. Mr. Garcia seconded the motion, which carried unanimously.

Board Travel Requests

a. NC Compounding Summit, Chapel Hill, NC February 24-26, 2026

Dr. Spigener moved to approve two board members, staff, and advice counsel to attend.
Dr. Tippins seconded the motion, which carried.

Dr. Spigener amended his previous motion to include up to four board members, all interested staff and advice counsel. Dr. Eunice seconded the motion, which carried.

b. MPJE Item Development, Mount Prospect, IL March 11-13, 2026

Dr. Spigener moved to send two staff members to this event. Ms. Farfone seconded the motion, which carried.

c. SCSHP Annual Meeting, Kiawah, SC March 11-13, 2026

Dr. Spigener moved to send two staff members to this meeting. Dr. Tippins seconded the motion, which carried.

d. NABP Annual Meeting, Boston, MA May 12-15, 2026

Dr. Gillespie moved to send up to five staff members and up to three board members and advice counsel to the annual meeting. Ms. Black seconded the motion, which carried.

Dr. Gillespie moved to go into executive session for legal advice and to include Dr. Shealy. Dr. Spigener seconded to motion, which carried.

Dr. Spigener moved to come out of executive session. Mr. Garcia seconded the motion, which carried.

No motions or decisions were made while in executive session.

APPLICANT APPEARANCES

Request Approval of Pharmacy Technician Application-Chelsey S. Stroman

The applicant's appearance is continued.

Request Approval to Renew Registration and Clarification on 2015 Consent Agreement-Carla M. Coulter

The applicant rescheduled appearance for the January 14, 2026 Board meeting.

Request Approval of Pharmacy Technician Application-Ikia Williams

The applicant's appearance is continued.

Request Approval of Pharmacy Technician Application-Kynisha A. Roberts

Dr. Spigener moved to approve the PHT application. Dr. Gillespie seconded the motion, which carried.

Request Approval of Pharmacy Technician Application-Travey Mason

Dr. Spigener moved to approve the PHT application. Dr. Gillespie seconded the motion, which carried.

Request Approval of Reinstatement of Pharmacist License-Richard G. Rumage, Jr.

Dr. Spigener moved to approve the reinstatement of pharmacist license. Dr. Gillespie seconded the motion, which carried.

ADJOURN-Dr. Spigener moved to adjourn the meeting until the following day. Mr. Garcia seconded the motion, which carried unanimously.

South Carolina Board of Pharmacy Board Meeting

9:00 A.M., November 20, 2025

Synergy Business Park

110 Centerview Drive, Columbia, South Carolina
Kingstree Building, Lowcountry Conference Room

Thursday, November 20, 2025

NON-RESIDENT APPLICATION HEARING

Request Approval of Non-Resident Pharmacy Application-Blue Door Pharmacies, LLC DBA: Shady Grove Pharmacy-Sheila Alizadeh, PharmD, PIC

The applicant requested to withdraw the application.

Dr. Spigener moved to go into executive session to seek legal advice. Mr. Garcia seconded the motion, which carried.

Dr. Spigener moved to come out of executive session. Ms. Black seconded the motion, which carried.

No motions or decisions were made while in executive session.

HEARINGS

In the Matter of:

Case# 2022-174

Mr. Garcia moved to accept the MOA with a five thousand (\$5,000) fine to be paid within 90 days of this order, with the stipulation that Respondent must submit quarterly reports for the next two years. Failure to comply with this order will result in an administrative suspension. Dr. Spigener seconded the motion, which carried.

Case# 2023-133

Dr. Spigener moved to accept the MOA, assess a fine of fifteen hundred dollars (\$1,500) payable within ninety (90) days of this order, require Respondent to complete twenty (20) hours of non-sterile compounding continuing education within six (6) months of the date of this order. Failure to comply in part or in whole with any terms of this order shall result in administrative suspension. Additionally, it is required that any failed inspection within the next three (3) years shall mandate a personal appearance before the Board for review and further action deemed appropriate.

Dr. Spigener amended his motion to include Accreditation Council for Pharmacy Education (ACPE) as part of the twenty (20) hours of non-sterile compounding continuing education and training. Ms. Black seconded the motion, which carried.

Case# 2025-4

Dr. Gillespie moved to reject the MOA and dismiss the case with a letter of caution. Dr. Spigener seconded the motion, which carried.

Case# 2025-37

Ms. Farfone moved to reject the MOA. Mr. Garcia seconded the motion, which carried.

COMPOUNDING REGULATIONS DRAFTING PROCESS

Dr. Spigener moved to go into executive session for legal advice relating to compounding regulations, to include Dr. Shealy. Ms. Black seconded the motion, which carried.

Ms. Black moved to exit the executive session. Mr. Garcia seconded the motion, which carried.

During the executive session, no decisions were made, and no motions were filed.

Dr. Smith stated that the Board can anticipate discussing this topic in future board meetings.

PUBLIC COMMENTS

There were no public comments.

ADJOURN

Dr. Spigener moved to adjourn. Dr. Gillespie seconded the motion, which carried.